small molecule

PREVYMIS

LETERMOVIR

Loss of exclusivityAugust 2031FDA regulatory exclusivity expiry

CompanyMERCK SHARP AND DOHME LLC

Drug detail

Brand name	PREVYMIS
Active ingredient	LETERMOVIR
Strength	20MG/PACKET
Dosage form	PELLETS
Route	ORAL
Modality	Small molecule
FDA approval	August 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
RE46791	January 2029	substance, product

Regulatory exclusivity

Code	Expires
ODE-495	August 2031
ODE-497	August 2031
ODE*	June 2030
NP	August 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from MERCK SHARP AND DOHME LLC